Daily Policy Digest
|Washington Update: A Review of 2015 and a Preview of 2016
From Washington, D.C., NCPA Legislative Director Brian Williams reviews a year of changes....
|To Control Drug Prices, Pursue Fraud, Not Manufacturers
There is a better way to control escalating drug costs that by trying to control drug prices...
|Private Health Construction Leads Slow Building Market
In a turnaround from September, private health construction grew strongly, (0.6 percent) while public health construction starts collapsed -2.5 percent...
|Interview with Dr. Bill Conerly -- Part Two
In the second of our two-part video series, NCPA Senior Fellow Dr. Bill Conerly, says that Americans should avoid relying solely on housing as an investment...
|More Evidence of School System Failure, But not of "Failure of Market Reform"
A new book documents that another attempt to significantly improve the school system central plan has failed, and that education scholars nearly always have no idea what "market reform" means, writes NCPA Senior Fellow John Merrifield...
|Obamacare Beneficiaries' Bleak Future
As more insurers decide to quit, 10 million Obamacare subscribers will be left high and dry in short order, writes NCPA Senior Fellow John R. Graham in the Daily Caller...
|Debating the Death of the American Dream
Is the American Dream lost? "No", says NCPA Director of Youth Programs Rachel Stevens in an InsideSources commentary...
|Health Services Spending Growing Faster Than Personal Consumption Expenditures
Obamacare is not bending the cost curve, writes NCPA Senior Fellow John R. Graham...
|Interview with Dr. Bill Conerly - Part One
Are we in for another housing crisis?...
|Pharmaceutical Marketing, the FDA and Free Speech
The U.S. Justice Department and state attorneys general have repeatedly used the threat of prosecutions for drugmakers touting off-label uses of pharmaceuticals to wring billions of dollars in settlements, fines and civil damages from them.